Cargando…
Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice
Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metaboli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328801/ https://www.ncbi.nlm.nih.gov/pubmed/34368611 http://dx.doi.org/10.1002/jbm4.10526 |
_version_ | 1783732375056809984 |
---|---|
author | Gerber, Claire Wang, Xueyan David, Valentin Quaggin, Susan E. Isakova, Tamara Martin, Aline |
author_facet | Gerber, Claire Wang, Xueyan David, Valentin Quaggin, Susan E. Isakova, Tamara Martin, Aline |
author_sort | Gerber, Claire |
collection | PubMed |
description | Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)(2)D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)(2)D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. |
format | Online Article Text |
id | pubmed-8328801 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83288012021-08-06 Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice Gerber, Claire Wang, Xueyan David, Valentin Quaggin, Susan E. Isakova, Tamara Martin, Aline JBMR Plus Original Articles Sodium‐glucose cotransporter 2 (SGLT2) inhibitors improve kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). However, bone fragility has emerged as a side effect in some but not in all human studies. Because use of SGLT2 inhibitors in humans affects mineral metabolism, we investigated the long‐term effects of genetic loss of Sglt2 function on bone and mineral metabolism in mice. Slc5a2 nonsense mutation in Sweet Pee (SP) mice results in total loss of Sglt2 function. We collected urine, serum, and bone samples from 15‐week‐old and 25‐week‐old wild‐type (WT) and SP mice fasted from food overnight. We measured parameters of renal function and mineral metabolism and we assessed bone growth, microarchitecture, and mineralization. As expected, 15‐week‐old and 25‐week‐old SP mice showed increased glucosuria, and normal kidney function compared to age‐matched WT mice. At 15 weeks, SP mice did not show alterations in mineral metabolism parameters. At 25 weeks, SP mice showed reduced fasting 24‐hour urinary calcium excretion and increased fractional excretion of phosphate, but normal serum calcium and phosphate, parathyroid hormone (PTH), vitamin D (1,25(OH)(2)D), and fibroblast growth factor (FGF23) levels. At 25 weeks, but not at 15 weeks, SP mice showed reduced body weight compared to WT. This was associated with reduced femur length at 25 weeks, suggesting impaired skeletal growth. SP mice did not show trabecular or cortical bone microarchitectural modifications but showed reduced cortical bone mineral density compared to WT mice at 25 weeks. These results suggest that loss of Sglt2 function in mice in the absence of T2DM does not alter regulatory hormones FGF23, PTH, and 1,25(OH)(2)D, but may contribute to bone fragility over the long term. Future studies are required to determine how loss of Sglt2 function impacts bone fragility in T2DM. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2021-07-06 /pmc/articles/PMC8328801/ /pubmed/34368611 http://dx.doi.org/10.1002/jbm4.10526 Text en © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Gerber, Claire Wang, Xueyan David, Valentin Quaggin, Susan E. Isakova, Tamara Martin, Aline Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title | Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title_full | Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title_fullStr | Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title_full_unstemmed | Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title_short | Long‐Term Effects of Sglt2 Deletion on Bone and Mineral Metabolism in Mice |
title_sort | long‐term effects of sglt2 deletion on bone and mineral metabolism in mice |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328801/ https://www.ncbi.nlm.nih.gov/pubmed/34368611 http://dx.doi.org/10.1002/jbm4.10526 |
work_keys_str_mv | AT gerberclaire longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice AT wangxueyan longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice AT davidvalentin longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice AT quagginsusane longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice AT isakovatamara longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice AT martinaline longtermeffectsofsglt2deletiononboneandmineralmetabolisminmice |